Theratechnologies Inc.
Theratechnologies Inc. (TH.TO) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Theratechnologies Inc. (TH.TO), featuring income statements, balance sheets, and cash flow data.
Theratechnologies Inc. (TH.TO) Income Statement & Financial Overview
View the income breakdown for Theratechnologies Inc. TH.TO across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $19.05M | $25.002M | $22.60M | $22.02M |
| Cost of Revenue | $3.48M | $6.10M | $4.52M | $4.55M |
| Gross Profit | $15.56M | $18.91M | $18.08M | $17.47M |
| Gross Profit Ratio | $0.82 | $0.76 | $0.80 | $0.79 |
| R&D Expenses | $2.97M | $5.88M | $2.61M | $4.72M |
| SG&A Expenses | $10.70M | $12.10M | $9.25M | $9.46M |
| Operating Expenses | $13.67M | $17.99M | $11.87M | $14.18M |
| Total Costs & Expenses | $17.15M | $24.08M | $16.39M | $18.73M |
| Interest Income | $9000.00 | $355000.00 | $364000.00 | $342000.00 |
| Interest Expense | $1.13M | $2.42M | $2.66M | $2.69M |
| Depreciation & Amortization | $491000.00 | $493000.00 | $405000.00 | $1.26M |
| EBITDA | $2.04M | -$3.97M | $6.62M | $4.47M |
| EBITDA Ratio | $0.11 | -$0.16 | $0.29 | $0.20 |
| Operating Income | $1.90M | $919000.00 | $6.21M | $3.29M |
| Operating Income Ratio | $0.10 | $0.04 | $0.27 | $0.15 |
| Other Income/Expenses (Net) | -$1.47M | -$7.80M | -$2.37M | -$2.18M |
| Income Before Tax | $424000.00 | -$6.88M | $3.85M | $1.10M |
| Income Before Tax Ratio | $0.02 | -$0.28 | $0.17 | $0.05 |
| Income Tax Expense | $307000.00 | $1.02M | $756000.00 | $118000.00 |
| Net Income | $117000.00 | -$7.90M | $3.09M | $987000.00 |
| Net Income Ratio | $0.006 | -$0.32 | $0.14 | $0.04 |
| EPS | $0.002 | -$0.15 | $0.06 | $0.02 |
| Diluted EPS | $0.002 | -$0.16 | $0.06 | $0.02 |
| Weighted Avg Shares Outstanding | $49.36M | $51.52M | $51.52M | $49.36M |
| Weighted Avg Shares Outstanding (Diluted) | $50.40M | $49.37M | $49.37M | $49.37M |
The company's financials show resilient growth, with revenue advancing from $22.02M in Q2 2024 to $19.05M in Q1 2025. Gross profit remained healthy with margins at 82% in Q1 2025 compared to 79% in Q2 2024. Operating income hit $1.90M last quarter, sustaining a consistent 10% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $2.04M. Net income rose to $117000.00, while earnings per share reached $0.002. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan